Tempus AI announced a new decision by the Centers for Medicare and Medicaid Services (CMS) that will allow reimbursement for assessments of cardiac dysfunction using the Tempus ECG-AF algorithm. This milestone enables Tempus to more broadly support clinicians in identifying patients at increased risk of atrial fibrillation/flutter (AF).
Per the CMS policy for Software as a Service (SaaS) devices in the Hospital Outpatient setting, associated procedure codes (CPT 0764T and CPT 0765T) for Tempus’ ECG-AF have been assigned to APC 5734. This assignment carries a Medicare rate of $128.90, effective January 1, 2025.
This ruling is expected to allow hospitals to receive reimbursement for using Tempus’ ECG-AF, substantially lowering the barrier for broad adoption of this innovative technology. The device, which received FDA 510(k) clearance earlier in the year, detects signs associated with a patient experiencing AF within the next 12 months for patients 65 years or older without a known history of AF.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.